Vitura Health’s EBITDA Climbs 23.5% to $7.63 Million in FY2025

Financial Performance Highlights

Vitura Health Limited (ASX – VIT) has delivered a solid FY2025 financial performance, with revenue increasing marginally by 0.14% to $124.04 million. More notably, EBITDA surged 23.5% to $7.63 million, reflecting disciplined cost management and operational efficiencies amid a challenging market environment. However, net profit after tax fell 5.8% to $3.06 million, impacted by higher amortisation of intangible assets, increased interest expenses, and elevated tax charges linked to capitalised IT costs.

Strategic Acquisitions and Patient Growth

The company’s growth strategy has been underpinned by key acquisitions that significantly expanded its patient reach. The acquisition of Candor Medical added approximately 15,000 active clinic patients, while the joint venture acquisition of Releaf Group assets through Flora Holdings potentially opens access to an additional 30,000 patients. The subsequent acquisition of Heyday Medical further broadened Vitura’s clinic footprint and expertise. These moves complement Vitura’s existing telehealth and medicinal cannabis distribution platforms, reinforcing its position in the digital health sector.

Telehealth Business Momentum

Vitura’s Doctors on Demand telehealth business was a standout performer, with revenues soaring 230% year-on-year. The platform saw a 58% increase in monthly consultations, surpassing 375,000 for the year, and daily consultations regularly exceeding 1,200. This growth was supported by the introduction of new fee structures and expanded service offerings, driving both B2C and B2B revenue streams. The integration of Candor Medical’s digital platform into the broader network is expected to further accelerate this momentum.

Technology and Operational Advances

Vitura completed the acquisition of the Canview technology platform, enhancing connectivity between patients, prescriptions, and medication distribution. The platform now supports over 4,800 pharmacies and 2,700 doctors nationwide, facilitating seamless medicinal cannabis dispensing. The company also expanded its product range and supplier agreements, while trialling operational shifts in distribution centres to improve service delivery. These initiatives position Vitura to capitalize on evolving healthcare delivery trends.

Leadership and Strategic Reset

Under the leadership of CEO Geoff Cockerill, appointed in November 2024, Vitura has undergone a strategic reset focused on execution and growth. The board and executive team have been refreshed, with new appointments strengthening operational and technological capabilities. The company resolved all material legacy legal and regulatory disputes, reducing risk and management distraction. The strong backing from major shareholder Professor Khalil (Charlie) Shahin AO further endorses the company’s strategic direction.

Outlook and Dividend

Looking ahead, Vitura targets continued revenue and EBITDA growth in FY2026, driven by full integration of recent acquisitions, operational efficiencies, and ongoing innovation. The board declared a fully franked final dividend of 0.2 cents per share, reflecting a commitment to shareholder returns alongside growth initiatives. More detailed guidance will be provided at the upcoming Annual General Meeting.